Brinter Inc
Brinter is a pioneering US-based MedTech firm focused on revolutionizing tissue engineering through the development of 3D bioprinted biocomposite regenerative implants, known as BioMods™, which aim to restore damaged tissue and replace conventional implants, launching in orthopedics/tendons and ligaments. The company driven by a team of visionary entrepreneurs and leading bioscientists and engineers.
Brinter Inc
Brinter Inc is currently seeking investment
Brinter Inc is seeking a series-a investment in the range of 1m-5m
What We Do
3D Bioprinted Biocomposite Implants
Brinter develops 3D-bioprinted biocomposite regenerative implants, or BioMods™, providing superior alternatives for human tissue repair. These fully resorbable implants are engineered to deliver greater strength, support faster healing, and serve a wide range of applications in orthopedics and sports medicine.
Brinter CORE
Brinter CORE is a patented multimaterial 3D bioprinter engineered to fabricate bio-synthetic medical devices with capabilities never before seen in the industry. Its advanced architecture enables precise deposition of multiple biomaterials in a single build, unlocking complex structures, enhanced mechanical performance, and true tissue-mimetic designs. Brinter CORE sets a new benchmark for next-generation implant manufacturing, from regenerative orthopedics to aesthetic and soft-tissue reconstruction.
Application Area
Show LessFDA Regulated Medical Devices
Routes of Administration
Digital Health Technologies
Key People
News & Updates
Brinter, a leader in 3D-bioprinted regenerative implants, has been recognized by TIME Magazine as one of the Best Inventions of 2025, highlighting the company’s breakthrough approach to next-generation medical devices. Each year, TIME selects innovations that are reshaping their industries and pushing the boundaries of what’s possible. Brinter earned its place on the prestigious list for pioneering BioMods™—3D-bioprinted biocomposite implants designed to strengthen tissue repair, accelerate healing, and offer fully resorbable alternatives to traditional orthopedic and soft-tissue solutions. The recognition reflects Brinter’s rapid advancement in both technology and clinical impact. With its patented Brinter CORE multi-material bioprinting platform and a pipeline of regenerative implants targeting orthopedics and aesthetics, the company is redefining how the world approaches human reconstructive care. This milestone comes as Brinter continues its regulatory progress, including submitting its Q-Sub to the FDA—a key step on the path toward U.S. market clearance. Brinter’s inclusion in TIME’s Best Inventions list underscores its position at the forefront of biofabrication and signals a major leap forward in the future of regenerative medicine.